Molecular Templates logoMolecular Templates Inc (NASDAQ:MTEM) has obtained a mean rating of “Hold” from the 11 scores companies which are presently protecting the inventory, MarketBeat Ratings reviews. Three equities research analysts have rated the inventory with a promote score and 7 have assigned a buy score to the company. The average twelve-month target charge amongst brokerages that have issued a document at the inventory inside the closing yr is $15.00.
Several studies analysts have lately weighed in on MTEM shares. Zacks Investment Research downgraded Molecular Templates from a “hold” score to a “sell” score in a studies be aware on Friday, August 16th. UBS Group commenced insurance on Molecular Templates in a research observe on Monday, April twenty ninth. They issued a “purchase” rating and a $12.00 goal price for the agency. Cowen restated a “purchase” rating on stocks of Molecular Templates in a studies word on Tuesday, August thirteenth. BidaskClub downgraded Molecular Templates from a “maintain” rating to a “sell” score in a research observe on Friday, July twenty sixth. Finally, TheStreet downgraded Molecular Templates from a “c-” score to a “d” rating in a research word on Monday, August 5th.
MTEM inventory opened at $five.00 on Thursday. The organization has a debt-to-fairness ratio of 0.15, a short ratio of 3.11 and a contemporary ratio of 3.Eleven. The organization has a marketplace capitalization of $193.Fifty five million, a charge-to-income ratio of -4.Ninety and a beta of 2.Seventy seven. Molecular Templates has a fifty-two week low of $3.19 and a fifty-two week high of $8.77. The stock has a fifty day shifting common of $6.Forty one and a two hundred-day moving average of $6.Forty eight.
Molecular Templates (NASDAQ:MTEM) ultimate published its quarterly profits consequences on Monday, August twelfth. The biotechnology organization mentioned ($0.25) income in keeping with proportion for the area, lacking the consensus estimate of ($0.23) by means of ($zero.02). The firm had sales of $five.Forty five million for the sector, as compared to the consensus estimate of $6.00 million. Molecular Templates had a negative go back on fairness of 27.Seventy two% and a terrible internet margin of 113.85%. Equities analysts expect that Molecular Templates will put up -zero.92 EPS for the contemporary yr.
A quantity of hedge price range and other institutional buyers have these days changed their holdings of the commercial enterprise. BlackRock Inc. Boosted its function in stocks of Molecular Templates by fifty one.1% at some stage in the second zone. BlackRock Inc. Now owns 1,080,557 stocks of the biotechnology organization’s stock worth $nine,023,000 after acquiring an additional 365,350 stocks during the last quarter. Point72 Asset Management L.P. Bought a brand new stake in stocks of Molecular Templates during the 2nd region worth approximately $1,682,000. Vanguard Group Inc. Boosted its position in shares of Molecular Templates via 10.4% at some stage in the 2d sector. Vanguard Group Inc. Now owns 740,883 shares of the biotechnology organization’s stock valued at $6,187,000 after obtaining an extra 69,704 stocks over the last zone. Renaissance Technologies LLC boosted its position in shares of Molecular Templates by using 453.7% at some point of the second quarter. Renaissance Technologies LLC now owns 81,400 stocks of the biotechnology company’s stock valued at $680,000 after acquiring an additional sixty six,700 stocks over the last quarter. Finally, Wells Fargo & Company MN boosted its role in stocks of Molecular Templates by using 557.7% in the course of the second region. Wells Fargo & Company MN now owns seventy eight,381 stocks of the biotechnology corporation’s stock valued at $654,000 after obtaining a further sixty six,464 shares over the past quarter. Institutional buyers and hedge funds personal 38.29% of the enterprise’s inventory.
About Molecular Templates
Molecular Templates, Inc, a scientific stage oncology organization, focuses on the discovery and development of biologic therapeutics for the remedy of cancer and different illnesses. The corporation primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse big B-cellular lymphoma; and Phase II medical trial for treating non-Hodgkin’s lymphoma.